JW생명과학 234080

 http://comp.fnguide.com/SVO2/asp/SVD_Main.asp?pGB=1&gicode=A234080&cID=&MenuYn=Y&ReportGB=&NewMenuID=101&stkGb=701

JW생명과학(A234080) | Snapshot | 기업정보 | Company Guide

- 해외수출 모멘텀은 2024년부터 현재주가 (1/30) 12,350원 - 
  한국IR협의회 - 2024.02.01 1706743987924.pdf (pstatic.net)
- 국내 시장점유율 1위 수액제 제조 및 개발 기업 - 이베스트증권 - 2023.01.31
  analysis.downpdf (hankyung.com)
- 다시 주목할 시기 임박 매수 (유지) 현재주가 (10 / 22 ) 23,500 원 목표주가 32,000 원 (유지)
  상승여력 36.2% - 신한투자 - 2018.10.23
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=497683
- 성장 가능성이 높지만 비싸지 않은 기업 Not Rated 현재가 (18/05/16) 23,200 원 - 
  키움증권 - 2018.05.17 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=477899
- EU GMP 인증 획득 Not Rated 현재가 (4/17, 원) 59,000 - KB증권 - 2018.04.18 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=473105
- 새로운 시작 매수 (유지) 현재주가 (4 월 9 일) 57,800 원 목표주가 81,000 원(상향) 
  상승여력 40.1% - 신한투자 - 2018.04.10
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=471980
- EU-GMP 인증 획득 Not Rated 현재주가 (4.2) 52,100 원 - 메리츠종금 - 2018.04.03 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=470890
- 해외시장 진출 기대감에 상승 53,700원 (+4.47%) - 2018.02.20
  ▷유화증권은 동사에 대해 올해 하반기부터 초도물량 납품 예정인 美 Baxter社와의 10년간 
  약 1조원 규모 물량 납품 계약을 통해 본격적인 글로벌 종합영양수액 시장 진출이라는 확실한 
  모멘텀을 보유하고 있다고 밝힘.
  특히, 마진이 높은 해외물량 납품 증가를 통해 동사의 마진 또한 계속해서 개선될 것으로 전망.
  ▷아울러 주식 액면분할, 배당 확대 등 주주가치 제고를 위한 노력도 긍정적이라고 분석.
  ▷투자의견 : 매수[유지], 목표주가 : 49,500원 → 63,000원[상향]
- 본격화 되는 박스터向 수출 모멘텀 매수 (유지) 현재주가 (1/ 16 ) 50,000 원 TP 62,000 원(상향)
  상승여력 24.0% - 신한투자 - 2018.01.17
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=460390
- 2018년에 진가가 드러난다 매수 (유지) 주가 (11/ 14) 40,550 원 목표주가 48,000 원 (유지)
  상승여력 18.4% - 신한투자 - 2017.11.15
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=452583

- 안정적 성장 지속 Not Rated -  KB증권 - 2017년 10월 23일
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=448040 
- 돋보이는 성장성에 주목하자 매수 (유지) 현재주가 (7/12 ) 33,200 원 TP 43,000 원 (상향) -
  신한투자 - 2017.07.13 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=434915
- 기초수액제재 이외에 영양수액, 특수수액의 강점 보유 -
  유안타증권 -2017.06.01- 유안타20170601JW생명과학.pdf  
- "투자의견 매수, 목표주가 36,000원"- 신한투자 -2017.05.17 - 신한20170517JW생명과학.pdf